NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NetTargets

NetTargets

Private
DaejeonHealthcare & Life Scienceshttps://www.net-targets.com/

Last Round

VC Round

May 1, 2024

Total Funding Raised

$7.17M

Company Overview

NetTargets is a biotechnology company that provides a drug discovery platform based on AI-enhanced systems biology to identify novel drug targets and simulate treatment strategies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

antibody-drug conjugatesADConcology therapeuticsdrug discoveryai drug discoverysystems biologydual-payload adccancer researchbiotech platformtarget identificationprecision medicinedrug resistancein silico drug discoverybiotech partneringai bio

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NetTargets Comparables

Compare NetTargets with similar companies based on industry and business-model similarity.

NetTargets comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Callio Therapeutics
83%
Phrontline Biopharma
83%
Eli Lilly and Company
75%

NetTargets Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMay 1, 2024
Series AJun 28, 2021
Pre SeedApr 16, 2020
SeedOct 25, 2019

Key People

Founding team and executive leadership

Je-Hoon Song

CEO (co-founder)

Founding Team

NetTargets Investors

Notable investors and investment history

NetTargets investors
InvestorRounds
DA Value InvestmentSeries A
CKD Venture CapitalSeries A
Bluepoint PartnersSeed
Friend Investment PartnersPre Seed, Series A
GU Equity PartnersSeries A
We VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 30, 2025

    Developing dual-payload ADCs with Debiopharm to treat resistant cancers.

  • Oct 30, 2025

    Collaborating with Debiopharm on dual-payload Antibody-Drug Conjugates (ADCs).

NetTargets Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NetTargets Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NetTargets's valuation, stock price, and market status.

Firmographic Details

HeadquartersDaejeon
Employee Range18
Year Founded2019
Last FundingMay 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.